



AstraZeneca Pharma India Limited

Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND TWELVE MONTHS ENDED 31 DECEMBER 2010

Rs In lakhs (except for number of shares)

| Sl No. | Particulars | 3 months ended | 3 months ended | Year to date | Previous |
|--------|--|-----------------|-----------------|---|----------------------------------|
| | | 31.12.2010 | 31.12.2009 | figures for current period ended 31.12.2010 | accounting year ended 31.12.2009 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | (a) Net sales (net of excise duty) | 12,845.04 | 11,484.89 | 45,105.73 | 38,552.12 |
| | (b) Other operating Income: - Service Income* | 407.25 | 139.08 | 1,629.09 | 1,111.21 |
| 2 | Expenditure | | | | |
| | (a) (Increase) / decrease in stock-in-trade and work-in-progress | (838.18) | (67.71) | (1,299.17) | 12.78 |
| | (b) Consumption of raw materials and packing materials | 1,602.63 | 1,331.35 | 5,963.86 | 4,675.41 |
| | (c) Purchase of traded goods | 3,175.12 | 2,219.64 | 9,262.29 | 7,507.77 |
| | (d) Employee cost | 2,542.19 | 1,828.59 | 11,220.15 | 8,282.94 |
| | (e) Depreciation | 185.37 | 156.38 | 705.65 | 807.87 |
| | (f) Other expenditure | 2,458.99 | 2,920.18 | 12,855.72 | 10,398.26 |
| | (g) Total | 9,128.14 | 8,388.43 | 38,746.60 | 31,384.81 |
| 3 | Profit from operations before other income, interest & exceptional items (1-2) | 4,126.15 | 3,235.54 | 7,986.22 | 8,278.52 |
| 4 | Other Income | 153.32 | 116.36 | 408.35 | 574.40 |
| 5 | Profit before interest & exceptional items (3+4) | 4,279.47 | 3,351.90 | 8,394.57 | 8,852.92 |
| 6 | Interest | - | - | - | 13.70 |
| 7 | Profit after interest but before exceptional items (5-6) | 4,279.47 | 3,351.90 | 8,394.57 | 8,839.22 |
| 8 | Exceptional items | - | - | - | - |
| 9 | Profit from ordinary activities before tax (7+8) | 4,279.47 | 3,351.90 | 8,394.57 | 8,839.22 |
| 10 | Tax expense | 1,447.31 | 1,143.29 | 2,816.99 | 3,077.49 |
| 11 | Net profit from ordinary activities after tax (9-10) | 2,832.16 | 2,208.61 | 5,577.58 | 5,761.73 |
| 12 | Extraordinary item | - | - | - | - |
| 13 | Net profit for the period (11-12) | 2,832.16 | 2,208.61 | 5,577.58 | 5,761.73 |
| 14 | Paid-up equity share capital (Face value of Rs 2 per equity share) | 500.00 | 500.00 | 500.00 | 500.00 |
| 15 | Reserves excluding revaluation reserves as per the balance sheet of previous accounting year | - | - | - | 13,951.82 |
| 16 | Basic and diluted earnings (Rs) per share (not annualised) | 11.33 | 8.83 | 22.31 | 23.05 |
| 17 | Public shareholding | | | | |
| | - Number of shares | 2,500,050 | 2,500,050 | 2,500,050 | 2,500,050 |
| | - Percentage of shareholding | 10.0002% | 10.0002% | 10.0002% | 10.0002% |
| 18 | Promoters and promoter group shareholding | | | | |
| | a) Pledged / Encumbered | | | | |
| | - Number of shares | - | - | - | - |
| | - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | - | - | - | - |
| | - Percentage of shares (as a % of the total share capital of the Company) | - | - | - | - |
| | b) Non-encumbered | | | | |
| | - Number of shares | 22,499,950 | 22,499,950 | 22,499,950 | 22,499,950 |
| | - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 100% | 100% | 100% | 100% |
| | - Percentage of shares (as a % of the total share capital of the Company) | 89.9998% | 89.9998% | 89.9998% | 89.9998% |

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 08 February 2011.
- Status of investor complaints: a) Pending as on 1 October 2010 - NIL b) Received during the quarter - 4 c) Disposed off during the quarter - 4 d) Pending as on 31 December 2010 - NIL.
- The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April- March". Accordingly, the financial accounts and annual report for the year ending 31 March 2011 shall be for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011.
- 'Employee cost' and 'other expenditure' include reversal of accrual of bonus and IT outsourcing charges of Rs 285 lakhs and Rs 170.7 lakhs respectively, provided for on an estimated basis in the earlier quarters.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others', which comprises service income pertaining to clinical trials and co-promotion activities.
- Previous period figures have been regrouped / reclassified, wherever necessary to conform to the current period's presentation.

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Rs In lakhs

| Sl No. | Particulars | 3 months ended | Corresponding | 12 months ended | Previous |
|--------|-----------------------------------|------------------|--|------------------|----------------------------------|
| | | 31.12.2010 | 3 months ended in the previous year 31.12.2009 | 31.12.2010 | Accounting year ended 31.12.2009 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Segment Revenue | | | | |
| | (a) Healthcare | 12,850.94 | 11,488.61 | 45,128.21 | 38,583.37 |
| | (b) Others | 407.25 | 139.08 | 1,629.09 | 1,111.21 |
| | Total | 13,258.19 | 11,627.69 | 46,757.30 | 39,694.58 |
| | Less: Inter-segment Revenue | - | - | - | - |
| | Net Income From Operations | 13,258.19 | 11,627.69 | 46,757.30 | 39,694.58 |
| 2 | Segment Results | | | | |
| | Profit before Tax and Interest | | | | |
| | (a) Healthcare | 4,077.58 | 3,233.40 | 7,847.06 | 8,288.13 |
| | (b) Others | 54.47 | 5.87 | 161.64 | 23.65 |
| | Total | 4,132.05 | 3,239.27 | 8,008.70 | 8,309.78 |
| | Add: Other Income | 147.42 | 112.63 | 385.87 | 543.14 |
| | Less: Interest | - | - | - | 13.70 |
| | Total Profit Before Tax | 4,279.47 | 3,351.90 | 8,394.57 | 8,839.22 |
| 3 | Capital Employed | | | | |
| | (a) Healthcare | 10,499.73 | 11,595.38 | 10,499.73 | 11,595.38 |
| | (b) Others | 24.65 | (378.11) | 24.65 | (378.11) |
| | (c) Unallocated | 9,514.67 | 3,234.55 | 9,514.67 | 3,234.55 |
| | Total | 20,039.05 | 14,451.82 | 20,039.05 | 14,451.82 |

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

By Order of the Board of Directors
For ASTRAZENECA PHARMA INDIA LIMITED

Place : Bangalore
Dated : 08 February 2011

Anandh Balasundaram
Managing Director